Antibiotic MICs and short time-killing against Helicobacter pylori: therapeutic potential of kanamycin

被引:15
作者
Irie, Y
Tateda, K
Matsumoto, T
Miyazaki, S
Yamaguchi, K
机构
[1] TOHO UNIV, SCH MED, DEPT MICROBIOL, OHTA KU, TOKYO 143, JAPAN
[2] TOHO UNIV, SCH MED, DEPT INTERNAL MED 3, MEGURO KU, TOKYO 153, JAPAN
关键词
D O I
10.1093/jac/40.2.235
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We compared the susceptibility of Helicobacter pylori to several antibiotics, expressed as MICs and as bactericidal effectiveness in short (3 h) time-killing studies. Of the antimicrobial agent tests, clarithromycin and amoxycillin had the lowest MIC50, 0.063 and 0.125 mg/L respectively, for 24 strains of H. pylori. Minocycline, levofloxacin and lansoprazole followed, with MIC(50)s of 0.5, 1, and 2 mg/L, respectively. Three-hour time-killing studies using a standard strain demonstrated a different pattern. At 4 x MIG, kanamycin, metronidazole and clarithromycin produced 4.4, 2.6 and 2.1 log decreases in viability, whereas the remaining seven antibiotics (including amoxycillin) were less bactericidal. Amoxycillin's lack of bactericidal activity during brief incubations was confirmed by examining several different clinically isolated H. pylori strains. Clarithromycin's effect, on the other hand, was strain-and concentration-dependent. Kanamycin was the most potent antibiotic in short time-killing studies, with concentrations of 1 x MIC and 4 x MIC producing a reduction of more than 2 and 4 log respectively in all ten strains. Our data suggest that the MIC of antimicrobial agents against H. pylori does not necessarily predict their activity in short time-killing studies. Furthermore, our short time-kill data suggest kanamycin as a potential therapeutic choice for H. pylori infection, even though this agent's MIC would suggest limited activity.
引用
收藏
页码:235 / 240
页数:6
相关论文
共 25 条
[1]   DUODENAL-ULCER - THE VILLAIN UNMASKED [J].
AXON, AR .
BRITISH MEDICAL JOURNAL, 1991, 302 (6782) :919-921
[2]   HELICOBACTER-PYLORI INFECTION [J].
AXON, ATR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 :61-68
[3]  
BARBERIS C, 1989, INT CONGR SER, V847, P581
[4]   BACTERICIDAL AND MORPHOLOGICAL EFFECTS OF AMOXICILLIN ON HELICOBACTER-PYLORI [J].
BERRY, V ;
JENNINGS, K ;
WOODNUTT, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) :1859-1861
[5]   HELICOBACTER-PYLORI - ITS ROLE IN DISEASE [J].
BLASER, MJ .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (03) :386-393
[6]   MONOTHERAPY OR POLYCHEMOTHERAPY IN THE TREATMENT OF CAMPYLOBACTER-PYLORI-RELATED GASTRODUODENAL DISEASE [J].
BORSCH, G ;
MAI, U ;
MULLER, KM .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1988, 23 :101-106
[7]   LOCAL GASTRIC AND SERUM AMOXICILLIN CONCENTRATIONS AFTER DIFFERENT ORAL APPLICATION FORMS [J].
COOREMAN, MP ;
KRAUSGRILL, P ;
HENGELS, KJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (07) :1506-1509
[8]   UTILIZATION OF TIME-KILL KINETIC METHODOLOGIES FOR ASSESSING THE BACTERICIDAL ACTIVITIES OF AMPICILLIN AND BISMUTH, ALONE AND IN COMBINATION, AGAINST HELICOBACTER-PYLORI IN STATIONARY AND LOGARITHMIC GROWTH PHASES [J].
COUDRON, PE ;
STRATTON, CW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (01) :66-69
[9]  
GLUPCZYNSKI Y, 1993, ZBL BAKT-INT J MED M, V280, P227
[10]  
GLUPCZYNSKI Y, 1990, AM J GASTROENTEROL, V85, P1545